Shanghai, October 16th (Xinhua) -- At every CIIE, the medical equipment and healthcare exhibition area is always "new" and full of satisfaction, always gathering a large number of high-tech debut, debut, and exhibition exhibits, becoming one of the hottest exhibition areas.
In 2023, the world's leading biopharmaceutical company Gilead Sciences will participate in the CIIE for the second time. From "first-time customers" to "returning customers", Gilead Sciences' "luggage" capacity has greatly increased: the exhibition area has expanded by 5 times, the innovative product business display area has expanded by 2 times, and a dedicated R&D pipeline exhibition area has been opened to introduce Gilead Sciences' global R&D pipeline layout and clinical research and new product launch plans in China.
In 2024, Gilead Science will hold hands with the China International Import Expo for the third time, expanding its "luggage" once again. It will showcase its continuously expanding product portfolio and innovative achievements on a 500 square meter booth, fully demonstrating its medical innovation strength and excellent practices in close collaboration with various partners to benefit Chinese patients. The exhibits not only cover the fields of virology, oncology, and mycology that Gilead China focuses on, but also include multiple investigational drugs that are being showcased for the first time. Jin Fangqian, Global Vice President and General Manager of Gilead Science in China, also expressed his great expectations for the three visits to the "CIIE Agreement".
Frequent occurrences of 'Jinbo Baby'
Gilead Sciences is headquartered in Foster City, California, USA and operates in over 35 countries and regions worldwide. In 2017, Gilead Sciences began commercial operations in China. In the past 7 years, 11 globally leading drugs from Gilead Sciences have been approved in China, of which 8 drugs have been included in the national medical insurance catalog.
China is one of the three important strategic markets for Gilead Sciences globally. Gilead Science has participated in the CIIE twice, witnessing the "spillover effects" brought by the CIIE and experiencing the rapid launch of exhibited drugs.
In the medical equipment and healthcare exhibition area of the CIIE, exhibitors are accustomed to affectionately referring to the innovative drugs and devices that have been transformed into products through the CIIE and implemented in China as "CIIE babies".
Every year after the CIIE, a group of "CIIE babies" are born. After participating in the CIIE for the first time in 2022, Gilead Science successfully obtained its own "CIIE baby", including two new drugs in the fields of antifungal and oncology. Among them, the antifungal drug Ampicillin& reg; Just three months after the exhibition, it obtained market approval from the China National Medical Products Administration, witnessing the accelerating pace of innovative drugs in China.
At the 6th CIIE in 2023, Gilead Science's "star product" long-acting HIV drug Lenacapavir, which was planned to be launched in China, attracted a lot of attention upon its debut.
Jin Fangqian believes that the CIIE has provided important assistance in promoting the overall process of innovative drug launch and has become an accelerator for promoting drug innovation and development.
Expand the "ecosystem" of medical cooperation
Having participated twice, the CIIE has gradually become an accelerator for promoting the development of Gilead Science in China. With the help of this open platform, Gilead Science continues to deepen its cooperation and exchanges with various parties.
At the 5th Expo, Gilead Science and the China Foundation for the Prevention of STDs and AIDS launched a three-year follow-up management cooperation project for hepatitis C cases to support the national action to eliminate the public health hazards of hepatitis C.
At the 6th World Expo, Gilead Science signed a cooperation agreement with the Chinese Association for the Prevention and Control of STD and AIDS on HIV fast start projects, advocating that HIV infected people get standardized treatment as soon as possible, and cooperated with the Beijing Sisco Clinical Oncology Research Foundation to establish the "Sisco Gilead Cancer Research Fund" to promote the transformation of scientific research in the field of cancer.
These projects are a vivid reflection of Gilead Science's deepening cooperation and win-win relationship with the Chinese medical ecosystem through the CIIE. Jin Fangqian said that he looks forward to using the CIIE platform to further expand his "circle of friends" in the medical ecosystem.
Increase R&D investment in China
As an important platform for foreign-funded enterprises to share China's development opportunities, the CIIE has become an important channel for global leading pharmaceutical companies to connect with the Chinese market. By participating in the China International Import Expo, Gilead Science has personally experienced the platform effect of "exhibits turning into commodities", deeply appreciated China's determination to share development opportunities with countries around the world, and further strengthened its confidence in rooted in the Chinese market and deeply cultivating local pharmaceutical innovation.
Nowadays, the Chinese market has become an international consensus as "the world's market, the shared market, and everyone's market". Since 2022, Gilead China has vigorously invested in local research and development, launching multiple clinical research projects, including Phase III clinical research and development synchronized with the world, covering multiple diseases in the fields of cancer and virology, aiming to promote more innovative therapies to be "simultaneously" launched in China and benefit more patients in need.
Gilead Sciences is committed to breaking through the impossible. Jin Fangqian stated that in the future, Gilead Sciences will continue to focus on patients, explore innovative cooperation with all parties, strengthen multi-channel construction, continuously improve the accessibility of marketed drugs, and continue to promote the construction of local research and development capabilities, so that more innovative drugs can benefit Chinese patients as soon as possible. (End)